The patient was initially treated for an abdominal aortic aneurysm (aaa) with an afx2 bifurcated stent graft and two (2) afx vela suprarenals.Approximately two (2) years and six (6) months post initial procedure the routine follow-up identified implant movement, an endoleak at an indeterminate origin and component-overlap decrease to 2cm.At reintervention it was determined that it was a type ii endoleak (non-device related).The physician elected to deploy an afx vela infrarenal and an afx vela suprarenal to increase the overlap and mitigate future disconnection.Reportedly, the patient tolerated the procedure well.
|
The reported adverse event/incident was investigated in alignment with endologix operating procedures and work instructions.Where possible, it is endologix practice to make at least three good faith efforts to retrieve a reported adverse event/incident related device as well as medical records and medical imaging.An evaluation of the manufacturing record was completed.A review of the part number/lot number combination needed for device identification shows the device to have been properly manufactured and released in accordance with the device master record.An evaluation of the device could not be completed.The device was not returned to endologix for evaluation because it remains implanted.A clinical evaluation of the adverse event/incident was completed.An examination of medical records and/or medical imaging received by endologix shows the implant movement and type ii endoleak event/incident are unconfirmed.This is not consistent with the reported adverse event/incident.Procedure related harms, device, user, procedure or anatomy relatedness of this complaint could not be determined with the medical records available for review.The final patient status was reported as being discharged on the fifth post-operative day to a skilled nursing facility.No additional investigation of this reported adverse event/incident is planned.However, should additional information relevant to the investigation outcome become available, a follow-up report will be submitted.Endologix will continue to monitor this and similar adverse events/incidents.Device iteration is afx2.H6: investigation finding codes: remove code 3233.H6: investigation conclusion codes: remove code 11.
|